Cognition Therapeutics Inc. (CGTX)
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
Catalyst Biosciences Inc. (CBIO)
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Neurogene Inc. (NGNE)
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Organon & Co. (OGN)
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
EDAP TMS S.A. (EDAP)
EDAP Reports Third Quarter 2025 Financial Results
Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Collegium Pharmaceutical Inc (COLL)
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
Plus Therapeutics Inc (PSTV)
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
Silence Therapeutics, Plc. (SLNCF)
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Johnson & Johnson (JNJ)
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder